BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 25300933)

  • 21. Concurrent chemotherapy and first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) with or without an antiangiogenic agent as first-line treatment in advanced lung adenocarcinoma harboring an EGFR mutation.
    Xu Z; Hao X; Lin L; Li J; Xing P
    Thorac Cancer; 2021 Aug; 12(16):2233-2240. PubMed ID: 34180588
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype.
    Metro G; Chiari R; Duranti S; Siggillino A; Fischer MJ; Giannarelli D; Ludovini V; Bennati C; Marcomigni L; Baldi A; Giansanti M; Minotti V; Crinò L
    Lung Cancer; 2012 Oct; 78(1):81-6. PubMed ID: 22770374
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas.
    Yu HA; Sima CS; Hellmann MD; Naidoo J; Busby N; Rodriguez K; Riely GJ; Kris MG
    Cancer; 2015 Jun; 121(12):2078-82. PubMed ID: 25781862
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Coexistence of p16/CDKN2A homozygous deletions and activating EGFR mutations in lung adenocarcinoma patients signifies a poor response to EGFR-TKIs.
    Jiang J; Gu Y; Liu J; Wu R; Fu L; Zhao J; Guan Y
    Lung Cancer; 2016 Dec; 102():101-107. PubMed ID: 27987577
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice.
    Fiala O; Pesek M; Finek J; Krejci J; Ricar J; Bortlicek Z; Benesova L; Minarik M
    Neoplasma; 2013; 60(1):26-32. PubMed ID: 23067213
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05).
    Zappa F; Droege C; Betticher D; von Moos R; Bubendorf L; Ochsenbein A; Gautschi O; Oppliger Leibundgut E; Froesch P; Stahel R; Hess T; Rauch D; Schmid P; Mayer M; Crowe S; Brauchli P; Ribi K; Pless M;
    Lung Cancer; 2012 Dec; 78(3):239-44. PubMed ID: 23009726
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutations of the EGFR and K-ras genes in resected stage I lung adenocarcinoma and their clinical significance.
    Ohba T; Toyokawa G; Kometani T; Nosaki K; Hirai F; Yamaguchi M; Hamatake M; Seto T; Ichinose Y; Sugio K
    Surg Today; 2014 Mar; 44(3):478-86. PubMed ID: 23609009
    [TBL] [Abstract][Full Text] [Related]  

  • 28. KRAS mutation in patients with lung cancer: a predictor for poor prognosis but not for EGFR-TKIs or chemotherapy.
    Guan JL; Zhong WZ; An SJ; Yang JJ; Su J; Chen ZH; Yan HH; Chen ZY; Huang ZM; Zhang XC; Nie Q; Wu YL
    Ann Surg Oncol; 2013 Apr; 20(4):1381-8. PubMed ID: 23208128
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Relationship between EGFR and KRAS mutations and prognosis in Chinese patients with non-small cell lung cancer: a mutation analysis with real-time polymerase chain reaction using scorpion amplification refractory mutation system].
    Gao J; Chen JQ; Zhang L; Liang ZY
    Zhonghua Bing Li Xue Za Zhi; 2012 Oct; 41(10):652-6. PubMed ID: 23302304
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil.
    de Melo AC; Karen de Sá V; Sternberg C; Olivieri ER; Werneck da Cunha I; Fabro AT; Carraro DM; de Barros e Silva MJ; Pimenta Inada HK; de Mello ES; Soares FA; Takagaki T; Ferreira CG; Capelozzi VL
    Oncology; 2015; 89(3):175-86. PubMed ID: 25833149
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas.
    Johnson ML; Sima CS; Chaft J; Paik PK; Pao W; Kris MG; Ladanyi M; Riely GJ
    Cancer; 2013 Jan; 119(2):356-62. PubMed ID: 22810899
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of epidermal growth factor receptor and K-ras mutation status in cytological stained smears of non-small cell lung cancer patients: correlation with clinical outcomes.
    Lozano MD; Zulueta JJ; Echeveste JI; Gúrpide A; Seijo LM; Martín-Algarra S; Del Barrio A; Pio R; Idoate MA; Labiano T; Perez-Gracia JL
    Oncologist; 2011; 16(6):877-85. PubMed ID: 21572125
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exon 19 deletion was associated with better survival outcomes in advanced lung adenocarcinoma with mutant EGFR treated with EGFR-TKIs as second-line therapy after first-line chemotherapy: a retrospective analysis of 128 patients.
    Wang Y; Li RQ; Ai YQ; Zhang J; Zhao PZ; Li YF; He WJ; Xia YX; Li WH
    Clin Transl Oncol; 2015 Sep; 17(9):727-36. PubMed ID: 26041721
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and long-term survival of advanced lung adenocarcinoma patients with uncommon EGFR mutations treated with 1st generation EGFR-TKIs compared with chemotherapy as first-line therapy.
    Li H; Wang C; Wang Z; Hu Y; Zhang G; Zhang M; Zheng X; Zhang X; Yang J; Ma Z; Wang H
    Lung Cancer; 2019 Apr; 130():42-49. PubMed ID: 30885350
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed.
    Camidge DR; Kono SA; Lu X; Okuyama S; Barón AE; Oton AB; Davies AM; Varella-Garcia M; Franklin W; Doebele RC
    J Thorac Oncol; 2011 Apr; 6(4):774-80. PubMed ID: 21336183
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.
    Khambata-Ford S; Harbison CT; Hart LL; Awad M; Xu LA; Horak CE; Dakhil S; Hermann RC; Lynch TJ; Weber MR
    J Clin Oncol; 2010 Feb; 28(6):918-27. PubMed ID: 20100958
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas.
    Paik PK; Johnson ML; D'Angelo SP; Sima CS; Ang D; Dogan S; Miller VA; Ladanyi M; Kris MG; Riely GJ
    Cancer; 2012 Dec; 118(23):5840-7. PubMed ID: 22605530
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations.
    Kim MH; Kim HR; Cho BC; Bae MK; Kim EY; Lee CY; Lee JS; Kang DR; Kim JH
    Lung Cancer; 2014 May; 84(2):196-202. PubMed ID: 24629638
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC.
    Kalikaki A; Koutsopoulos A; Trypaki M; Souglakos J; Stathopoulos E; Georgoulias V; Mavroudis D; Voutsina A
    Br J Cancer; 2008 Sep; 99(6):923-9. PubMed ID: 19238633
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.
    Yu JY; Yu SF; Wang SH; Bai H; Zhao J; An TT; Duan JC; Wang J
    Chin J Cancer; 2016 Mar; 35():30. PubMed ID: 27001083
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.